Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alimta in advanced or metastatic bladder cancer
NCT00035061Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in transitional cell carcinoma of the urothelium (TCC), sponsored by Eli Lilly and Company. Primary endpoint: Objective Response Rate. Status: completed.
02
Drugs
pemetrexed
03
Conditions
transitional cell carcinoma of the urothelium (TCC)
Beyond the preview
Go deeper on NCT00035061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035061.